Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung

Basit Öğe Kaydı
dc.contributor.authorGoss, G.
dc.contributor.authorLee, K. H.
dc.contributor.authorFelip, E.
dc.contributor.authorCobo, M.
dc.contributor.authorSyrigos, K.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgioulias, V.
dc.contributor.authorGuclu, S. Z.
dc.contributor.authorIsla, D.
dc.contributor.authorMin, Y. J.
dc.contributor.authorMorabito, A.
dc.contributor.authorDupuis, N.
dc.contributor.authorChand, V. K.
dc.contributor.authorSolca, F.
dc.contributor.authorKraemer, N.
dc.contributor.authorGibson, N.
dc.contributor.authorEhrnrooth, E.
dc.contributor.authorSoria, J. C.
dc.date.accessioned2019-10-27T11:25:30Z
dc.date.available2019-10-27T11:25:30Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.sponsorshipBoehringer IngelheimBoehringer Ingelheimen_US
dc.description.sponsorshipBoehringer Ingelheimen_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://hdl.handle.net/11454/33394
dc.identifier.volume27en_US
dc.identifier.wosWOS:000393913000330en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEvaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lungen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu